Department of Nephrology and Transplantation, Erasmus University Medical Center, Rotterdam, The Netherlands.
PLoS One. 2013 Jul 29;8(7):e70152. doi: 10.1371/journal.pone.0070152. Print 2013.
The presence of monocyte-macrophage lineage cells in rejecting kidney transplants is associated with worse graft outcome. At present, it is still unclear how the monocyte-macrophage related responses develop after transplantation. Here, we studied the dynamics, phenotypic and functional characteristics of circulating monocytes during the first 6 months after transplantation and aimed to establish the differences between kidney transplant recipients and healthy individuals.
Phenotype, activation status and cytokine production capacity of classical (CD14++CD16-), intermediate (CD14++CD16+) and non-classical (CD14+CD16++), monocytes were determined by flow cytometry in a cohort of 33 healthy individuals, 30 renal transplant recipients at transplantation, 19 recipients at 3 months and 16 recipients at 6 months after transplantation using a cross-sectional approach.
The percentage of both CD16+ monocyte subsets was significantly increased in transplant recipients compared to healthy individuals, indicative of triggered innate immunity (p≤0.039). Enhanced production capacity of tumor necrosis factor-α, interferon-γ and interleukin-1β was observed by monocytes at transplantation compared to healthy individuals. Remarkably, three months post-transplant, in presence of potent immunosuppressive drugs and despite improved kidney function, interferon-γ, tumor necrosis factor-α and interleukin-10 production capacity still remained significantly increased.
Our data demonstrate a skewed balance towards pro-inflammatory CD16+ monocytes that is present at the time of transplantation and retained for at least 6 months after transplantation. This shift could be one of the important drivers of early post-transplant cellular immunity.
在排斥反应的肾移植中,单核细胞-巨噬细胞谱系细胞的存在与移植后更差的移植物结果相关。目前,尚不清楚移植后单核细胞-巨噬细胞相关反应是如何发展的。在这里,我们研究了移植后前 6 个月循环单核细胞的动力学、表型和功能特征,并旨在确定肾移植受者与健康个体之间的差异。
采用流式细胞术检测 33 名健康个体、30 名移植时的肾移植受者、19 名移植后 3 个月和 16 名移植后 6 个月的经典(CD14++CD16-)、中间(CD14++CD16+)和非经典(CD14+CD16++)单核细胞的表型、激活状态和细胞因子产生能力。
与健康个体相比,移植受者的 CD16+单核细胞亚群的百分比明显增加,提示触发了固有免疫(p≤0.039)。与健康个体相比,移植时的单核细胞产生肿瘤坏死因子-α、干扰素-γ和白细胞介素-1β的能力增强。值得注意的是,移植后 3 个月,尽管存在强效免疫抑制药物和改善的肾功能,但干扰素-γ、肿瘤坏死因子-α和白细胞介素-10的产生能力仍然明显增加。
我们的数据表明,在移植时存在偏向促炎的 CD16+单核细胞的不平衡,并且在移植后至少 6 个月内仍然存在。这种转变可能是移植后早期细胞免疫的重要驱动因素之一。